Published in Cancer Weekly, December 7th, 1998
"We are pleased with both the response rate and the durability we have seen to date in this study," said Hollings Renton, Onyx. "We plan to submit the data from the head and neck cancer studies to the U.S. Food and Drug Administration...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.